Outcome of sentinel lymph node biopsy in breast cancer using dye alone: A single center review with a median follow-up of 5 years

Surgery Today

Volumn 44, Issue 9, 2014, Pages 1633-1637

  Ogawa, Yoshinari ^a   Ikeda, Katsumi ^a   Ogisawa, Kana ^a,b   Tokunaga, Shinya ^a   Fukushima, Hiroko ^a   Inoue, Takeshi ^a   Mori, Yoshihiro ^a   Tachimori, Akiko ^a   Inoue, Toru ^a   Nishiguchi, Yukio ^a  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

^b Ikuwakai Memorial Hospital   (Japan)

Author keywords

Breast; Dye; Indocyanine green; Prognosis; Sentinel lymph node

Indexed keywords

INDIGO CARMINE; INDOCYANINE GREEN; COLORING AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; SUBAREOLAR DRUG ADMINISTRATION; SURVIVAL RATE; BREAST NEOPLASMS; DIAGNOSTIC USE; FEASIBILITY STUDY; INJECTION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COLORING AGENTS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIGO CARMINE; INDOCYANINE GREEN; INJECTIONS; MIDDLE AGED; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; TIME FACTORS;

EID: 84906334704     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-013-0728-9     Document Type: Article

References (27)

1. Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595-600.
2. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol. 2010;11:927-33.
3. Zovagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, et al. A randomized clinical trial on sentinel node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207-13. (Pubitemid 351156760)
4. Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491-500.
5. Sasada T, Murakami S, Kataoka T, Ohara M, Ozaki S, Okada M, et al. Memorial Sloan-Kettering Cancer Center Nomogram to predict the risk of non-sentinel lymph node metastasis in Japanese breast cancer patients. Surg Today. 2012;42:245-9.
6. Tanaka S, Sato N, Fujioka H, Takahashi Y, Kimura K, Iwamoto M. Validation of online calculators to predict the non-sentinel lymph node status in sentinel lymph node-positive breast cancer patients. Surg Today. 2013;43:163-70.
7. Kern KA, Rosenberg RJ. Prospective lymphoscintigraphy during lymphatic mapping for breast cancer: improved sentinel node imaging using subareolar injection of technetium 99m sulfur colloid. J Am Coll Surg. 2000;191:479-89.
8. Povoski SP, Olsen JO, Young DC, Clarke J, Burak WE, Walker MJ, et al. Prospective randomized clinical trial comparing intradermal, intraparenchymal and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol. 2006;13:1412-21. (Pubitemid 44749652)
9. Halsell JT, Smith JR, Bentlage CR, Park OK, Humphreys JW Jr. Lymphatic drainage of the breast demonstrated by vital dye staining and radiography. Ann Surg. 1965;162:221-6.
10. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelly MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18:2553-9. (Pubitemid 30432521)
11. Hirche C, Murawa D, Mohr Z, Kneif S, Hünerbein M. ICG-fluorescence- guided sentinel node biopsy for axillary nodal staging in breast cancer. Breast Cancer Res Treat. 2010;121:373-8.
12. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133-44. (Pubitemid 47244357)
13. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599-609. (Pubitemid 43904843)
14. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391-401. (Pubitemid 24313232)
15. Haigh PI, Hansen NM, Qi K, Giuliano AE. Biopsy method and excision volume do not affect success rate of subsequent sentinel node dissection in breast cancer. Ann Surg Oncol. 2000;7:21-7. (Pubitemid 30078489)
16. Kaklamanos IG, Birbas K, Syrigos K, Bonatsos VG, Bonatsos G. Prospective comparison of peritumoral and subareolar injection of blue dye alone, for identification of sentinel lymph nodes in patients with early stage breast cancer. J Surg Oncol. 2011;104:37-40.
17. Kim T, Giuliano AE, Lyman GH. SLymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a meta analysis. Cancer. 2006;106:4-16. (Pubitemid 43033320)
18. Wong SL, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001;192:684-9.
19. Wang M, Zhou W, Zhao Y, Xia T, Zha X, Ding Q, et al. A novel finding of sentinel lymphatic channels in early stage breast cancer patients: which may influence detection rate and false-negative rate of sentinel lymph node biopsy. PLoS ONE. 2012;7:e51226.
20. Kapoor NS, Sim MS, Lin J, Giuliano AE. Long-term outcome of patients managed with sentinel lymph node biopsy alone for node-negative breast cancer. Arch Surg. 2012;147:1047-52.
21. van Wely BJ, van den Wildenberg FJ, Gobardham, P van Dalen T, Borel Rinkes IH, Theunissen EB, et al. Axillary recurrences after sentinel lymph node biopsy: a multicentre analysis and follow-up of sentinel lymph node negative breast cancer patients. J Cancer Surg. 2012;38:925-31.
22. de Kenter AY, Menke-Pluymers MM, Wouters MW, Burgmans I, van Geel AN, Eggermont AM. 5-year follow-up of sentinel node negative breast cancer patients. Euro J Surg Oncol. 2006;32:282-6.
23. Chua B, Ung O, Boyages J. Competing consideration in regional nodal treatment for early breast cancer. Breast J. 2002;8:15-22. (Pubitemid 34118479)
24. Louis-Sylvestre C, Clough K, Asselain B, Vicoq JR, Salmon RJ, Campana F, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol. 2004;22:97-101. (Pubitemid 41095119)
25. Kelley LM, Holmes DR. Tracer agents for the detection of sentinel lymph nodes in breast cancer: current concerns and directions for the future. J Surg Oncol. 2011;104:91-6.
26. Reyes FJ, Noelck MB, Valentino C, Grasso-LeBeau L, Lang JE. Complication of methylene blue dye in breast surgery: case reports and review of the literature. J Cancer. 2011;2:20-5.
27. Del Bianco P, Zavagno G, Burelli P, Scalco G, Barutta L, Carraro P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomized clinical trial. Euro J Surg Oncol. 2008;34:508-13. (Pubitemid 351514885)